Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 14/20 | 0.73 |
| ▸ | GLRB | P48167 | 14/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | SCN1A | P35498 | 1/20 | 0.71 |
| ▸ | TAS2R46 | P59540 | 1/20 | 0.71 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.71 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brucine SCHEMBL12293782 | 1.00 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL14029321 | 1.00 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL113229 | 1.00 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL1648976 | 1.00 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL29391712 | 1.00 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL23468158 | 1.00 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL19476145 | 1.00 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL6233075 | 0.99 | TAS2R10 (0.98) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL6794678 | 0.99 | TAS2R10 (0.98) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL7253414 | 0.99 | TAS2R10 (0.98) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8043823-B2 | Methods of identifying agonists and antagonists of hTASR bitter taste receptors | DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20100184796-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100130498-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | DEUTSHES INSTITUT FUR ERNAHRUNGSFORSCHUNG POTSDAM- REHBRUCKE (DE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TAS2R10 7/4885CHRM1 1252/4885SMN1; SMN2 2730/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | TAS2R10 7/4885CHRM1 1252/4885SMN1; SMN2 2730/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TAS2R10 7/4885CHRM1 1252/4885SMN1; SMN2 2730/4885 |
| US-20100184796-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | TAS2R50, TAS2R30, TAS2R60 | TAS2R10 10/4885CHRM1 858/4885SMN1; SMN2 4568/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TAS2R10 7/4885CHRM1 1252/4885SMN1; SMN2 2730/4885 |
| US-20100130498-A1 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | TAS2R10, TAS2R30, TAS2R20 | TAS2R10 1/4885CHRM1 964/4885SMN1; SMN2 4544/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TAS2R10 7/4885CHRM1 1252/4885SMN1; SMN2 2730/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TAS2R10 7/4885CHRM1 1252/4885SMN1; SMN2 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.